Discover comprehensive solutions with integrative care for OUD and chronic pain for a healthier, pain-free life. Transform your approach now.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this comprehensive educational post, I take you on a clear, step-by-step journey through modern, evidence-based care for opioid use disorder (OUD) and chronic pain. I explain, in plain language and physiologic detail, how and why the three FDA-approved medications for OUD — methadone, buprenorphine, and naltrexone — work at the mu-opioid receptor, when to use each, and how we safely initiate and maintain treatment in the fentanyl era. You will learn how traditional, low-dose (microdosing), and high-dose buprenorphine starts are selected and executed, why precipitated withdrawal happens, and how we prevent and treat it with careful timing, shared decision-making, COWS scoring, and symptom-targeted adjuncts.

Because many of my patients have chronic pain alongside OUD or opioid dependence, I explain why buprenorphine is uniquely suited for pain management — from its partial agonism and kappa antagonism to its lower risks of respiratory depression, tolerance, and hyperalgesia. I outline practical strategies for using transdermal (Butrans), buccal (Belbuca), sublingual (off-label for pain), and long-acting injectable (Sublocade, Brixadi) buprenorphine — including dosing, titration, administration pearls, and insurance considerations.

This post showcases our integrative, multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas. I work in formal collaboration with Dr. Maria Guadalupe Cardenas, MD, Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933), who serves as our Medical Director and Collaborative Physician. Together, we combine internal medicine oversight, chiropractic care, functional medicine, personal injury care, and rehabilitation to deliver safe, patient-centered, and outcome-focused treatment. I weave in clinical observations from my practice and publicly shared insights on my platforms to illuminate real-world decision-making.

You will leave with a deep understanding of:

• The pharmacology and clinical application of buprenorphine, methadone, and naltrexone (and how they differ).
• Modern buprenorphine initiation strategies that address illicit fentanyl’s unique pharmacokinetics.
• How integrative chiropractic and functional medicine enhance stabilization, relief, and long-term outcomes.
• Practical scripts, safety checklists, and harm reduction counsel that protect life and engagement.
• Special populations (pregnancy, perioperative, adolescents), personal injury patterns, and rehabilitation pillars.

Throughout, I cite leading researchers and professional bodies, link to references in APA-7 style, and translate complex science into actionable, compassionate care.

About Our Multidisciplinary Clinic in El Paso: Medical Direction, Chiropractic Integration, and Functional Medicine

I practice at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. Our model is a multidisciplinary, integrative framework common in progressive injury and rehabilitative care clinics. In this model, an MD provides medical direction alongside a chiropractor, ensuring a unified, safety-first, evidence-based approach to complex pain and OUD care.

• I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. My scope spans:

• • Chiropractic care for neuromusculoskeletal dysfunction, spinal biomechanics, and pain modulation.
  • Advanced practice nursing for comprehensive assessment, diagnostics, and prescribing, including buprenorphine.
  • Functional medicine to uncover systemic drivers (inflammation, nutrition, gut-brain factors, sleep, hormones).

• Dr. Maria Guadalupe Cardenas, MD — Board Certified in Internal Medicine, with more than 40 years of experience — serves as:

• • Medical Director and Collaborative Physician (NPI #1164426749; Texas MD License #J2933).
  • The linchpin of medical oversight, risk mitigation, and high-standard pharmacologic care.
  • The supervising physician ensures state-board-compliant collaborative practice and guards patient safety.

This integration lets us:

• Align buprenorphine, methadone transitions, and naltrexone decisions with rigorous internal medicine oversight.
• Pair medical stabilization with chiropractic adjustments, spinal decompression, myofascial work, and neurodynamic mobilization to reduce nociceptive drive and improve function.
• Apply functional medicine to lower systemic inflammation, support sleep, and optimize metabolic and gut-brain health.
• Coordinate rehabilitation for mobility, ergonomic strategies, strength, and graded exposure to activity.
• Deliver cohesive personal injury care and documentation with outcome tracking to demonstrate function and quality-of-life gains.

Clinical observations guiding this approach are reflected in my ongoing publications and posts:

• https://chiropracticscientist.com/
• https://www.linkedin.com/in/dralexjimenez/

Why Medications for Opioid Use Disorder Save Lives

When someone meets DSM-5 criteria for OUD, medications are first-line, lifesaving treatments. This is not just a preference; it is an evidence-based imperative.

• Reduced mortality: Retention on methadone or buprenorphine cuts all-cause and overdose mortality by more than half (Sordo et al., 2017).
• Stabilized physiology: These medications suppress withdrawal and cravings, allowing the brain’s reward and stress circuits to recalibrate.
• Restored function: Stabilization supports employment, relationships, self-care, and therapeutic engagement.
• Low-barrier care: Behavioral therapies help, but access to MOUD should not be contingent on therapy attendance. We meet patients where they are.

In our clinic, we prescribe naloxone broadly, practice harm reduction, and respect that readiness for change varies over time. My role is to provide the safest, most effective medical treatment available the moment a person asks for help.

References:

• Sordo, L., Barrio, G., Bravo, M. J., et al. (2017). Mortality risk during and after opioid substitution treatment. BMJ.

The Pharmacology That Matters: Full Agonist, Partial Agonist, Antagonist

All three FDA-approved OUD medications modulate the mu-opioid receptor (MOR), yet they do so differently, which is why their clinical roles diverge.

• Methadone: a full MOR agonist

• • As dose rises, receptor activation and effects rise proportionally until saturation.
  • Benefits: robust withdrawal suppression, craving control, potent blockade of exogenous opioids.
  • Risks: respiratory depression (especially with initiation, dose adjustments, and sedative co-use), QTc prolongation, and drug-drug interactions.

• Buprenorphine: a high-affinity, partial MOR agonist with a ceiling effect

• • High affinity displaces other opioids; partial intrinsic activity caps respiratory depression risk.
  • Adds kappa antagonism (less dysphoria/stress) and ORL-1 activity (anti-hyperalgesia potential).
  • Benefits: safety profile enables office-based treatment, strong cravings/withdrawal control, analgesia without pronounced euphoria.

• Naltrexone: a MOR antagonist

• • Blocks opioids entirely; no intrinsic activation.
  • Benefits: relapse prevention post-detox; overdose protection via receptor blockade.
  • Limitations: no relief of withdrawal/cravings; requires 7–10 days opioid-free to avoid precipitated withdrawal; blocks opioid analgesics needed for acute pain.

References:

• Buprenorphine pharmacology overview. (2024)
• ASAM Clinical Considerations: Buprenorphine for OUD. (2023)
• Lutfy, K., & Cowan, A. (2004). Buprenorphine: A unique drug with complex pharmacology. Current Neuropharmacology.

Buprenorphine Formulations and What They Are For

Because buprenorphine’s effect depends on formulation and dosing, the clinical context determines which tool I reach for.

• Buprenorphine monoproducts:

• • Subutex (sublingual tablet): OUD; risk of diversion led to widespread preference for combination products, yet mono remains critical for specific patients (e.g., intolerance to naloxone component).
  • Butrans (transdermal patch): FDA-approved for chronic pain only; low-dose continuous delivery (5–20 mcg/hour).
  • Belbuca (buccal film): FDA-approved for chronic pain; higher bioavailability than patch with broader dose range.
  • Buprenex (injectable): Acute pain in supervised settings.

• Buprenorphine/naloxone:

• • Suboxone (film or tablet), Zubsolv (tablet), Bunavail (buccal): OUD treatment in outpatient settings; naloxone deters injection misuse (poor sublingual bioavailability, high parenteral bioavailability).

• Long-acting injectables (LAIs):

• • Sublocade (monthly subcutaneous depot): OUD after> 7 days of stabilized SL buprenorphine 8–24 mg/day; steady state in 4–6 months; supplemental SL dosing often needed early.
  • Brixadi (weekly and monthly subcutaneous): OUD (monthly); weekly for OUD and pain in some jurisdictions; flexibility for dosing and emerging direct initiation pathways under defined protocols.

Clinical pearls:

• Combination products’ naloxone deters injection but does not provide therapeutic effect when taken sublingually.
• For patients with headaches or GI upset on combination products, mono-buprenorphine can improve tolerability — I document rationale and plan for continuity.

References:

• ASAM Clinical Considerations: Buprenorphine for OUD. (2023)

How I Teach Sublingual Administration to Protect Efficacy

Absorption matters. I coach patients to:

• Place the film/tablet under the tongue or against the cheek (for approved buccal products).
• Avoid chewing, talking, eating, or drinking until fully dissolved (~10 minutes or more).
• If nausea occurs after 10+ minutes, spit the remaining saliva to reduce GI upset; the drug works through mucosal absorption, not the stomach.

I also warn about rare dental issues (caries) reported with long-term SL use and recommend rinsing with plain water after dissolution, daily hygiene, and regular dental care.

References:

• FDA safety communications on dental concerns with buprenorphine (public notices; integrated into clinical practice guidance)

Precipitated Withdrawal: Why It Happens and How We Avoid It

When a high-affinity partial agonist displaces a full agonist from MORs and provides lower intrinsic activation, net receptor signaling crashes — the nervous system perceives a sudden deficit, triggering intense withdrawal.

Physiology that patients feel:

• Locus coeruleus disinhibition: noradrenergic surge, tachycardia, sweating, anxiety, tremor.
• Enteric rebound: diarrhea, cramping, vomiting.
• Pupillary dilation: sympathetic overdrive.
• Dysphoria and hyperalgesia: abrupt removal of full agonist analgesia and disrupted descending modulation.

How I prevent it:

• I ensure patients reach mild to moderate withdrawal before traditional induction (COWS> 11–13, and preferably higher in fentanyl exposure).
• In fentanyl scenarios, I often favor low-dose (microdosing) starts when avoidance of precipitated withdrawal is paramount.
• I use symptom-targeted adjuncts to blunt autonomic and GI symptoms and provide careful coaching.

Why this matters to the therapeutic alliance:

• A traumatic induction erodes trust and triggers disengagement or high-risk use. Prevention is an ethical and clinical priority.

References:

• ASAM Clinical Considerations. (2023)
• Buprenorphine pharmacology overview. (2024)

Fentanyl Changes Induction: Lipophilicity, Depot Effects, and Unpredictable Washout

Illicit fentanyl’s extreme lipophilicity allows sequestration in adipose tissue, with slow, unpredictable release. Patients can appear “ready” for a traditional start yet still have fentanyl trickling into circulation, increasing precipitated withdrawal risk even after prolonged abstinence.

Clinical implications:

• Traditional abstinence-first protocols are harder to tolerate and riskier in fentanyl exposure.
• Severe restlessness and anxiety can precede objective signs, complicating COWS-based timing.
• Many patients come with prior failed starts and fear of withdrawal; I build plans around their priorities.

Why shared decision-making is essential:

• In the fentanyl era, no single method fits all. I match the strategy to exposure history, goals, distress tolerance, clinical setting, and support system.

References:

• ASAM Clinical Considerations. (2023)
• Hughes, A. (2018). Pharmacokinetics of fentanyl and lipophilicity.

My Three Buprenorphine Initiation Pathways: Traditional, Low-Dose (Microdosing), and High-Dose

I select the method in partnership with the patient, respecting their experience, goals, and risks.

Traditional Induction: Structured, Familiar, and Best Without Fentanyl Confounds

When exposure is to short-acting full agonists (e.g., oxycodone, heroin) with minimal fentanyl involvement:

• Stop full agonists:

• • Short-acting: typically 12–24 hours.
  • Extended-release or methadone: 24–72+ hours.
  • Fentanyl: often ~48 hours — but risk remains due to depot effects.

• Start in mild to moderate withdrawal:

• • COWS> 11–13; higher thresholds may reduce risk further.

• Dosing:

• • Initial 2–8 mg; reassess every 1–2 hours; total Day 1 often 8–16 mg (sometimes 24 mg).
  • Day 2: Give total effective Day 1 dose; then adjust to maintenance (commonly 12–24 mg/day).

• Watch for worsening symptoms:

• • If precipitated withdrawal occurs, pause buprenorphine, manage symptoms (clonidine/ondansetron/NSAIDs, etc.), and reassess timing. In severe cases, a small full agonist dose may be needed to reset before retrying.

Advantages:

• Operationally simpler; no film cutting.

Limitations in fentanyl era:

• Higher risk of precipitated withdrawal despite long abstinence.
• Patient distress and attrition risk.

References:

• ASAM Clinical Considerations. (2023)
• Buprenorphine induction strategies. (2024)

Low-Dose (Microdosing) Initiation: Gentle Receptor Transition While Continuing Full Agonist

Ideal when patients fear withdrawal, need to maintain function, or have fentanyl exposure:

• Mechanism:

• • Introduce tiny buprenorphine doses while full agonist continues, gradually increasing buprenorphine to slowly occupy MORs and displace full agonist without abrupt signaling loss.

• Practical examples:

• • 4-day accelerated outpatient: microdoses escalated to ~8 mg/day by Day 3, with full agonist discontinued Day 4; then proceed to maintenance.
  • 6–7-day slower titration: start ~0.5 mg/day and increment daily; reach ~12 mg by Day 7; then optimize.

• Harm reduction:

• • If patients use illicit opioids during titration, I emphasize overdose prevention and naloxone. Significant overdose protection emerges around 8 mg/day and above.

• Considerations:

• • Requires cutting films and close coaching.
  • Success improves with structured follow-up and accessible support.

Advantages:

• Minimizes precipitated withdrawal risk.
• Patient-centered for those with low distress tolerance or ongoing pain needs.

Challenges:

• Logistics, precision, and daily engagement; completion rates vary in low-barrier settings, underscoring the value of support.

References:

• ASAM Clinical Considerations. (2023)
• Brar, R., et al. (2021). Low-dose buprenorphine microdosing literature.

High-Dose Induction: Rapid Stabilization With Structured Safety

Used in EDs and urgent care, adaptable to ambulatory care with careful monitoring:

• Criteria:

• • Confirm time since last use (fentanyl typically> 12 hours, but context matters).
  • COWS> 16 with> 2 objective signs (piloerection, pupillary dilation, rhinorrhea, diarrhea).

• Dosing:

• • Initial 8–16 mg (commonly 16 mg in fentanyl exposure).
  • Observe for 30 minutes; if tolerated, add 8 mg; up to 32 mg on Day 1.
  • Day 2: Continue 24–32 mg/day based on response.

• Advantages:

• • Fast relief; straightforward dosing.

• Risks:

• • If precipitated withdrawal occurs, intensity can be high; plan and counsel accordingly.

References:

• CA Bridge Buprenorphine Protocols. (2024)
• ASAM Clinical Considerations. (2023)

COWS With Clinical Wisdom: Objectivity and Nuance

The Clinical Opioid Withdrawal Scale (COWS) anchors safety thresholds, but fentanyl-related presentations can challenge strict interpretation. Severe restlessness and anxiety can precede other objective signs. I listen closely to patient narratives, use COWS judiciously, and balance scores with clinical context.

Reference:

• NIDA Clinical Resource. COWS tool and guidance. (2023)

Adjunct Medications I Use to Protect Engagement

Targeted symptom relief helps patients endure the transition and prevents disengagement:

• Autonomic and anxiety:

• • Clonidine for noradrenergic symptoms (monitor blood pressure).
  • Hydroxyzine for anxiety and sleep initiation.

• Musculoskeletal:

• • Tizanidine for muscle cramps and myalgias (blood pressure caution).
  • NSAIDs or acetaminophen for pain.

• GI:

• • Ondansetron for nausea/vomiting.
  • Loperamide for diarrhea.

• Sleep:

• • Trazodone as indicated.

Safety:

• Avoid stacking sedatives.
• Tailor to comorbid cardiovascular, hepatic, or renal conditions.
• Discuss expected benefits and side effects with the patient.

References:

• ASAM Clinical Considerations. (2023)
• Volkow, N., & Walgamuth, M. (2019). Adjunctive therapy in opioid withdrawal.

How I Integrate Chiropractic Care During Buprenorphine Initiation

Stabilizing the neurobiology of OUD with buprenorphine is necessary but not sufficient. Pain, deconditioning, and maladaptive mechanics often persist. This is where integrative chiropractic care adds unique value.

Neurophysiology and techniques:

• Manual therapies stimulate large-diameter afferents (A-beta), engaging segmental inhibitory mechanisms in the dorsal horn to gate nociception and reduce pain perception.
• Gentle mobilization, myofascial release, and graded neurodynamic techniques decrease peripheral nociceptive drive and sympathetic arousal.
• Postural retraining and ergonomic coaching lower mechanical strain, support sleep, and reduce flare-ups.

Clinical execution:

• I avoid high-velocity thrusts in hyperalgesic states or with contraindications (acute instability, severe osteoporosis).
• I coordinate with Dr. Cardenas on vitals (e.g., clonidine/tizanidine use) and medical comorbidities.
• I time sessions to support initiation milestones without overwhelming the patient.

Outcomes:

• Reduced nociceptive input lowers the risk of central sensitization.
• Enhanced function and sleep support medication adherence and mood.

References:

• Bialosky, J. E., et al. (2019). Manual therapies for pain modulation.
• Garland, E. L., et al. (2020). Functional integration in OUD recovery.

Functional Medicine Foundations That Improve Induction Resilience

I systematically address biology that shapes pain, mood, and neuroendocrine balance:

• Reduce systemic inflammation:

• • Mediterranean-style dietary pattern; omega-3 fatty acids; curcumin.

• Correct micronutrient deficits:

• • Magnesium (muscle relaxation, NMDA modulation), B vitamins (nerve health, energy).

• Support sleep and circadian rhythm:

• • Behavioral strategies; aligned nutraceuticals as needed.

• Heal the gut-brain axis:

• • Normalize bowel function, address dysbiosis, improve mucosal integrity.

Why this matters:

• Lower inflammation reduces hyperalgesia and emotional distress.
• Stable sleep and nutrition enhance executive function, adherence, and coping.

References:

• DiChiara, A. J., et al. (2018). Nutrition and inflammation in chronic pain.
• Finan, P. H., et al. (2019). Sleep and pain relationships.

Personal Injury Care and Rehabilitation: Restoring Function Safely

Many patients begin opioid therapy after injuries (MVAs, work-related strains, whiplash, radiculopathies). Rehabilitation becomes a cornerstone of recovery:

• Graded exposure and progressive loading:

• • Calm fear-avoidance, restore confidence in movement.

• Core stabilization and mobility:

• • Reduce mechanical stress on pain generators.

• Balance and proprioception:

• • Lower fall risk during early initiation when fatigue and anxiety may be present.

• Home programs:

• • Consistent routines that build autonomy and reinforce clinic gains.

References:

• Nijs, J., et al. (2017). Rehabilitation strategies in chronic musculoskeletal pain.
• Leeuw, M., et al. (2015). Graded activity and fear-avoidance.

Putting It All Together: Our Integrated Buprenorphine Initiation Pathway

How we operationalize care at Injury Medical Clinic PA:

• Intake and triage:

• • Medical evaluation by Dr. Cardenas; musculoskeletal and functional assessment by me.
  • Substance use history, last use timing, fentanyl likelihood, COWS scoring, patient goals.

• Method selection via shared decision-making:

• • We review traditional, low-dose, and high-dose pathways with individualized pros/cons.

• Adjunct plan:

• • Symptom-targeted prescriptions with clear safety guidance.
  • Harm reduction: naloxone for patient and household, overdose prevention, safer-use counsel if low-dose induction includes continued opioid use early on.

• Integrative care timing:

• • Chiropractic and functional supports aligned with induction milestones; no overload.

• Follow-up cadence:

• • Daily or near-daily touchpoints during low-dose inductions; structured observation for high-dose starts; next-day dose adjustments.

• Maintenance optimization:

• • Recognize that many fentanyl-exposed patients stabilize at 24–32 mg/day sublingual; document cravings, withdrawal suppression, and function for payer support.

References:

• ASAM Clinical Considerations. (2023)
• CA Bridge Protocols. (2024)

Practical Counseling Scripts I Use

• Expectation setting:

• • “You may feel anxious and restless before other withdrawal signs show up. That is common with fentanyl. We will treat those symptoms proactively.”

• Choosing a method:

• • “If avoiding withdrawal is your top priority, a low-dose start fits. It requires careful dosing and close check-ins.”
  • “If you want a fast transition and you are in solid withdrawal, a high-dose start can stabilize you quickly, but we will discuss precipitated withdrawal risk and our plan to manage it.”

• Harm reduction:

• • “If you continue to use during the first few days of a low-dose start, let’s double up on overdose prevention: carry naloxone, avoid using alone, test a small amount first.”

• Self-efficacy:

• • “Your experience guides us. Tell me exactly what you feel; we will adjust together. You are in control — we are here to support.”

Long-Acting Injectable Buprenorphine: Sublocade and Brixadi in Clinical Practice

Why LAIs are rising:

• Stable pharmacokinetics reduce daily peaks/troughs of sublingual dosing, potentially smoothing cravings and withdrawal.
• Improved adherence and reduced diversion; monthly or weekly structure enhances retention.
• May offer stronger opioid blockade in high-risk fentanyl exposure.

Sublocade pearls:

• Standard loading: 300 mg monthly for 2 months, then 100 mg monthly maintenance (some remain at 300 mg).
• Requires prior tolerance: 7 days on 8–24 mg/day sublingual.
• Steady state: 4–6 months; supplemental SL often needed initially.

Brixadi pearls:

• Weekly and monthly options; flexibility for titration and end-of-interval symptom coverage.
• Emerging evidence for supervised direct initiation of weekly formulation while in withdrawal (context-specific).
• Watch for end-of-month tail-off with monthly dosing; provide sublingual supplements when needed.

Access and logistics:

• Both products are under REMS; provider-clinic “buy-and-bill ” models; prior authorization common; cost is high.
• We maintain certification, supply chain, and billing workflows to remove access barriers for our patients.

A Patient-Centered Dosing Reality: Up to 32 mg/day When Clinically Indicated

In fentanyl-exposed patients, daily stabilization may require more than the traditional 24 mg/day ceiling. Evidence and evolving guidance now recognize that 24–32 mg/day can be medically necessary. My documentation includes:

• Persistent cravings and breakthrough symptoms at 24 mg/day.
• Improved function and symptom control at higher doses.
• COWS and clinical narratives supporting the therapeutic need.

Most payers increasingly accept 32 mg/day with medical justification. We manage prior authorizations and maintain ongoing assessments to match dose to outcomes.

Special Populations and Complex Transitions

• Methadone to buprenorphine:

• • Due to methadone’s long and variable half-life, microdosing is often safer than abstinence-first protocols and reduces precipitated withdrawal risk (Lintzeris et al., 2021).

• Benzodiazepine or alcohol co-use:

• • Increased sedation and overdose risk; cautious titration and non-pharmacologic supports; avoid punitive discontinuation that could destabilize care.

• Cardiometabolic disease:

• • Adjust clonidine or tizanidine in bradycardia/hypotension; consider alternatives.

• Pregnancy:

• • Buprenorphine is recommended; sublingual formulations (mono or combo) are acceptable; LAIs are not FDA-approved in pregnancy.
  • Doses often need to increase and be split during pregnancy to maintain effect; coordinate closely with obstetrics (ACOG, 2019).

• Perioperative:

• • Continue buprenorphine through surgery; build multimodal analgesia; coordinate with surgical teams; avoid destabilizing discontinuation.

• Adolescents (< 16 years):

• • Buprenorphine is FDA-approved; a clear, compassionate overdose prevention message is essential; emphasize that 8 mg/day provides meaningful blockade.

References:

• ACOG guidance on buprenorphine in pregnancy. (2019)
• Lintzeris, N., et al. (2021). Methadone-buprenorphine transitions.

Methadone: A Cornerstone Therapy Requiring Careful Titration and Legal Framework

What makes methadone powerful and risky:

• Full MOR agonist with slow onset; long, variable half-life (8–65 hours).
• Stacking effect during the first week; steady state reached over 4–7 days.
• Requires meticulous dose titration to avoid accumulation and respiratory depression.

Safety considerations:

• Drug-drug interactions via CYP3A4 and CYP2B6.
• QTc prolongation; baseline and follow-up ECGs as clinically indicated; avoid initiation if QTc >500 ms unless benefits outweigh risks (Krantz et al., 2004).

Regulation:

• For OUD, outpatient methadone must be dispensed at a certified Opioid Treatment Program (OTP). Hospitals can initiate and adjust methadone; discharge planning must include a confirmed OTP appointment. Up to a 3-day bridge supply may be dispensed at discharge to prevent gaps.

Ethics at discharge:

• If a hospitalized patient is not ready to stop all illicit use, we still give the discharge methadone dose and naloxone, plus reengagement resources — harm reduction keeps patients alive.

References:

• Mattick, R. P., et al. (2014). Methadone maintenance vs. no opioid therapy. Cochrane.
• Krantz, M., et al. (2004). Methadone and the QT interval.

Naltrexone: Role, Requirements, and Counseling

• Mechanism: Complete MOR blockade; prevents opioid effects.
• Role: Relapse prevention post-detox; not first-line for most due to no relief of withdrawal/cravings.
• Initiation: Requires 7–10 days opioid-free to avoid precipitated withdrawal; even tramadol counts.
• Dosing:

• • Oral: start 25 mg/day x 3 days, then 50 mg/day.
  • Injectable (Vivitrol): 380 mg IM every 4 weeks; some patients benefit from shorter intervals when effects fade late in the cycle.

• Pain caveat:

• • Naltrexone blocks opioid analgesics; perioperative planning must anticipate alternative pain control.

Buprenorphine for Chronic Pain: Why It Is Different and Often Safer

Why I often rotate chronic pain patients from full agonists to buprenorphine:

• Partial MOR agonism with a respiratory depression ceiling improves safety.
• Kappa antagonism may reduce dysphoria and the “suffering” component of pain.
• ORL-1 activity may dampen central sensitization and hyperalgesia.
• Lower risks of tolerance escalation and opioid-induced hyperalgesia.
• Less cognitive fog, constipation, and endocrine disruption compared to full agonists (e.g., reduced hypogonadism risk).

Clinical effects I see:

• Patients describe feeling clearer, more functional, and emotionally steadier.
• Stable analgesia without the peaks and troughs of short-acting full agonists.

References:

• Lutfy, K., & Cowan, A. (2004). Buprenorphine’s complex pharmacology.
• Webster, L. R. (2017). Science and safety of buprenorphine for chronic pain.

Practical Pain Formulations: Transdermal, Buccal, and Off-Label Sublingual

Butrans (Transdermal Patch) — Chronic Pain Only

• Doses: 5, 7.5, 10, 15, 20 mcg/hour; wear 7 days; max 20 mcg/hour.
• Best for: Opioid-naïve or < 80 MME/day (after tapering to < 30 MME/day before starting).
• Starting guide:

• • Opioid-naïve or <30 MME/day: 5 mcg/hour.
  • 30–80 MME/day: 10 mcg/hour.
  • 80 MME/day: Patch likely inadequate; consider Belbuca or SL off-label.

• Titration: Increase by 5–10 mcg/hour; wait 72 hours to assess the new dose.
• Breakthrough pain: Use short-acting analgesics early; taper as patch effect stabilizes.
• Administration pearls:

• Rotate sites (upper outer arm, upper chest/back, side of chest).
• Apply to clean, dry, hairless skin; avoid heat exposure (accelerates release).
• Do not abruptly stop; taper under supervision.

Belbuca (Buccal Film) — Chronic Pain Only

• Doses: 75–900 mcg per film; typically every 12 hours; max 900 mcg q12h.
• Higher bioavailability than patch; useful when more analgesia is needed.
• Starting guide (based on pre-taper MME):

• • <30 MME/day: 75 mcg q12h (or daily).
  • 30–89 MME/day: 150 mcg q12h.
  • 90–159 MME/day: 300 mcg q12h.
  • > 160 MME/day: 450 mcg q12h.

• Titration: Increase by 150 mcg increments q12h, no more than every 4 days; personalize.

Patch vs. buccal decision:

• I often start with patch for convenience and safety; if maxed without relief, transition to Belbuca.
• Discuss lifestyle, costs, and patient preference; align regimen with patient’s routine.

Off-Label Sublingual Buprenorphine for Complex Pain

For highly opioid-tolerant patients or those failing max doses of Butrans/Belbuca, sublingual buprenorphine (with or without naloxone) may be the only option that provides adequate analgesia and withdrawal prevention.

• Requires expertise in pain and buprenorphine pharmacology.
• Document rationale, assess for OUD, and monitor closely.
• Stabilize on divided dosing to match analgesic needs.

References:

• Webster, L. R. (2017). Buprenorphine for chronic pain.

Managing Side Effects and Setting Expectations in Pain Care

• Common early effects: Nausea, headache, mild stomach upset; often self-limited.
• Constipation: Milder than full agonists; counsel on hydration, fiber, stool softeners as needed.
• Patch site reactions: Rotate sites; consider mild topical corticosteroid if needed.
• Time to full effect:

• I tell patients that full analgesic effects can take up to 2 weeks — we titrate slowly and cover breakthroughs initially.

• Insurance and cost:

• • Prior authorization is common for Butrans/Belbuca; our team handles documentation; explore manufacturer assistance programs.

Harm Reduction Is Compassionate, Evidence-Based Care

Core messages I share with all patients on opioids or with ongoing illicit use:

• Illicit fentanyl is ubiquitous:

• • Any pill or powder may be fentanyl-adulterated; overdose risk is high.

• Naloxone saves lives:

• • Carry it like your keys or phone; train loved ones; recognize overdose signs (unresponsiveness, slow/stopped breathing, blue lips).

• Safer use strategies:

• • Prefer non-injection routes when possible; if injecting, use sterile supplies, alcohol swabs, and never share equipment; use sterile or distilled water.
  • Never use alone; test a small amount first; keep doses predictable.

• Community health:

• • Even if you never need naloxone for yourself, you may save a friend or family member.

I frame harm reduction as dignity, safety, and a bridge to recovery readiness — not as condoning use.

Outcome Tracking: How We Measure What Matters

We track clinical and functional outcomes to refine care and support payer justifications:

• Pain:

• • Numeric pain ratings; PROMIS Pain Interference; qualitative reports.

• Function:

• • Mobility tests; return to work or activities; home program adherence.

• Engagement:

• • Appointment attendance; medication persistence; craving reports.

• Quality of life:

• • Sleep quality; mood; social participation; patient-defined goals.

References:

• Cella, D., et al. (2015). PROMIS measures in chronic pain.

Case Vignettes From My Practice

• Patient A (fentanyl exposure, prior failed traditional start):

• • Chose low-dose microdosing with clonidine and hydroxyzine, plus gentle myofascial care and daily coaching.
  • Transitioned to 12 mg by Day 7; ultimately stabilized at 24 mg/day.
  • Sleep improved; returned to light-duty work.

• Patient B (ED high-dose start):

• • COWS 18, last fentanyl 14 hours prior; received 16 mg, then 8 mg.
  • Next-day clinic follow-up continued at 28 mg/day.
  • Chiropractic mobilization and ergonomic strategies reduced neck pain and fear-avoidance.

• Patient C (short-acting oxycodone, minimal fentanyl):

• • Traditional start after 24-hour abstinence: 4 mg to 16 mg on Day 1.
  • Ondansetron and NSAIDs for symptoms; postural retraining.
  • Stabilized at 16 mg/day with improved daily function.

Insurance and Access Realities

• Dosing caps:

• • Some payers cap at 24 mg/day; I document cravings and function to justify 24–32 mg/day in fentanyl exposure.

• LAI access:

• • REMS enrollment, buy-and-bill, and prior authorizations are standard; we maintain workflows to minimize patient burden.

Sustainability and Long-Term Recovery

As stabilization takes hold:

• Exercise progression and graded activity restore capacity and confidence.
• Nutrition and sleep frameworks sustain neuroendocrine balance.
• Ongoing counseling and peer supports buffer stressors and prevent relapse.
• Regular reassessment aligns dose and modalities with evolving goals.

References:

• McHugh, R. K., et al. (2020). Relapse prevention frameworks.

How Our Team Works Day-to-Day: Roles in an Integrative, Patient-Centered System

• Dr. Cardenas, MD (Internal Medicine):

• • Medical supervision and safety oversight for pharmacologic therapy.
  • Case review and guidance on comorbidities and polypharmacy.
  • Coordination with hospital and community providers (e.g., OTPs, EDs, OB/GYN, surgery).

• Dr. Jimenez, DC, APRN, FNP-BC (me):

• • Comprehensive assessments; lab and imaging as needed.
  • Buprenorphine induction and maintenance planning in collaboration with Dr. Cardenas; naltrexone counseling; hospital-to-clinic bridges.
  • Chiropractic adjustments, mobilizations, neurodynamic and myofascial work timed to induction phases.
  • Functional medicine plans for nutrition, sleep, gut-brain axis, micronutrients.
  • Rehabilitation programming, ergonomics, graded exposure, and outcome tracking.

• Administrative team:

• • Prior authorizations, LAI logistics, REMS compliance, billing support, and insurance navigation.

This symphony of roles ensures a safe medical backbone, neuro-musculoskeletal care that reduces nociception, and lifestyle supports that improve recovery durability.

Perioperative Buprenorphine: Why Continuation Is Best Practice

I regularly advise surgical teams:

• Do not stop buprenorphine perioperatively — discontinuation risks withdrawal, cravings, relapse, and overdose.
• Build multimodal analgesia (regional anesthesia, acetaminophen, NSAIDs, gabapentinoids as appropriate).
• Consider temporary dose adjustments in collaboration with addiction medicine support.
• Maintain clear communication about what buprenorphine does and does not block, and plan accordingly.

Practical Tips For Patients Starting Sublingual Buprenorphine

• Take in the morning for consistent daily rhythm; some benefit from split dosing early on for symptom control.
• Do not rush dissolution; set a timer to avoid talking, eating, or drinking.
• Rinse with water after absorption is finished; brush as part of daily dental hygiene routine.
• Keep a daily journal of symptoms, cravings, and sleep; bring it to check-ins.
• Carry naloxone and teach loved ones how to use it.

Integrative Chiropractic Care: Mechanisms, Methods, and Outcomes

Why manual care matters during OUD stabilization and pain recovery:

• Mechanism-level benefits:

• • Afferent input from adjustments and mobilizations gates nociception, modulates descending inhibitory pathways, and attenuates sympathetic overactivity.

• Techniques I use:

• • Low-velocity joint mobilization and gentle adjustments customized to tolerance.
  • Soft-tissue work (myofascial release, trigger point therapy) to address hypertonicity and adhesions.
  • Neurodynamic mobilization for radicular symptoms.
  • Postural retraining, core stabilization, and ergonomic coaching to reduce recurring strain.

Safety integration:

• I screen for red flags (osteoporosis, instability, vascular risks) and coordinate with Dr. Cardenas on anticoagulation, blood pressure, and acute medical issues.
• I adjust force and frequency based on pain sensitivity and medication changes.

Clinical outcomes:

• Improved range of motion, decreased pain intensity, better sleep, and higher confidence in movement.
• Lower reliance on breakthrough analgesics as mechanics improve.

References:

• Bialosky, J. E., et al. (2019). Manual therapies for pain modulation.

Functional Medicine Details: The “Why” Behind Each Lever

• Anti-inflammatory nutrition:

• • Omega-3s modulate eicosanoids; Mediterranean patterns reduce CRP and cytokine loads that amplify nociception.

• Magnesium:

• • Modulates NMDA receptors; supports skeletal muscle relaxation and sleep quality.

• Curcumin:

• • Broad anti-inflammatory effects via NF-KB pathways; adjunct for musculoskeletal pain.

• B vitamins:

• • Methylation and nerve support; energy metabolism for rehabilitation tolerance.

• Sleep hygiene:

• • Consistent schedules, light exposure, and caffeine timing improve HPA axis stability and pain thresholds.

• Gut-brain axis:

• • Post-opioid bowel dysfunction and dysbiosis are common; restoring motility and mucosal integrity reduces systemic inflammation and improves mood.

References:

• DiChiara, A. J., et al. (2018). Nutrition and inflammation.
• Finan, P. H., et al. (2019). Sleep and pain.

Patient Education Materials We Provide

• Buprenorphine basics: how timing prevents precipitated withdrawal; how partial agonism provides safety.
• Overdose prevention: naloxone usage, signs of overdose, never-use-alone strategies.
• Symptom guides: what is normal, what requires a call, when to seek urgent care.
• Movement and posture: at-home routines for pain reduction and sleep support.
• Insurance navigation: what to expect with prior authorizations and LAIs.

My Clinical Observations: What I See, Track, and Adjust

From my ongoing practice and posts (https://chiropracticscientist.com/; https://www.linkedin.com/in/dralexjimenez/):

• Fentanyl-exposed patients often need higher daily buprenorphine (24–32 mg/day) and benefit from early, proactive adjuncts for restlessness and insomnia.
• Low-dose induction completion improves with daily coaching and aligned chiropractic sessions that reduce mechanical flare-ups.
• Sustained improvements in sleep tend to predict stronger craving control and fewer relapse triggers.
• LAIs enhance retention for patients who struggle with daily medication tasks or stigma; supplemental SL in early months prevents end-interval dips.
• A structured rehabilitation progression, even modest at first, accelerates mood improvements and cuts fear-avoidance behaviors.

Closing Perspective: Why an Integrative, Team-Based Model Works

The fentanyl era demands adaptability, empathy, and precision. By uniting:

• Internal medicine oversight (Dr. Cardenas),
• Evidence-based addiction pharmacotherapy (methadone transitions, buprenorphine, naltrexone),
• Integrative chiropractic care,
• Functional medicine supports,
• Personal injury care and rehabilitation,
• Harm reduction and patient empowerment,

We maximize safety, reduce the risk of precipitated withdrawal, stabilize physiology, and rebuild function. Our patients do not just survive — they recover capacity, identity, and hope.

I am honored to do this work in El Paso, alongside Dr. Maria Guadalupe Cardenas, MD, and our dedicated team at Injury Medical Clinic PA. Together, we provide a modern, compassionate, evidence-based pathway for people living with OUD and chronic pain.

References

• (2019). Buprenorphine in pregnancy.
• (2023). Clinical Considerations: Buprenorphine for Opioid Use Disorder.
• Bialosky, J. E., Simon, C. B., Bishop, M. D., et al. (2019). The mechanisms of manual therapy in the treatment of musculoskeletal pain: A comprehensive model. Journal of Manual & Manipulative Therapy, 27(5), 231–241.
• Brar, R., Fairbairn, N., Sutherland, C., Nolan, S., & Socias, M. E. (2021). Use of low-dose buprenorphine induction for the treatment of opioid use disorder: A systematic review. Drug and Alcohol Dependence, 225, 108760.
• CA Bridge. (2024). Buprenorphine Quick Start Protocols.
• Cella, D., et al. (2015). PROMIS pain interference short form: Validity and responsiveness in adults with chronic pain. Pain, 156(5), 1003–1010.
• DiChiara, A. J., et al. (2018). Diet, inflammation, and chronic pain: An integrative review. Nutrition and Health, 24(3), 129–143.
• Finan, P. H., Goodin, B. R., & Smith, M. T. (2019). The association of sleep and pain: An update and a path forward. The Journal of Pain, 20(12), 124–142.
• Garland, E. L., Froeliger, B., Zeidan, F., Partin, K., & Howard, M. O. (2020). Mindfulness training targets neurocognitive mechanisms of addiction at the attention-appraisal-emotion interface: A neurocognitive framework and evidence from a randomized trial. PLoS One, 15(1), e0226581.
• Hughes, A. (2018). Pharmacokinetics of fentanyl relevant to its clinical use in pain management. Anesthesiology Clinics, 36(3), 401–415.
• Krantz, M. J., Martin, J., & Mehler, P. S. (2004). Methadone and the QT interval: A review of the evidence and clinical guidance. The American Journal of Medicine, 117(4), 257–262.
• Lintzeris, N., Dunlop, A. J., et al. (2021). Transferring patients from methadone to buprenorphine: A systematic review and clinical guidance. Addiction, 116(8), 2024–2037.
• Lutfy, K., & Cowan, A. (2004). Buprenorphine: A unique drug with complex pharmacology. Current Neuropharmacology, 2(4), 395–402.
• Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, (2).
• McHugh, R. K., Hearon, B. A., & Otto, M. W. (2020). Cognitive-behavioral therapy for substance use disorders. Psychiatric Clinics, 43(2), 1–16.
• (2024). Buprenorphine pharmacology overview.
• (2023). Clinical Opiate Withdrawal Scale (COWS).
• Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.
• Webster, L. R. (2017). A review of the science and safety of buprenorphine for chronic pain. Pain Medicine, 18(suppl_1), S14–S20.

SEO tags: buprenorphine, buprenorphine induction, microdosing buprenorphine, high-dose buprenorphine, traditional induction, precipitated withdrawal, fentanyl lipophilicity, methadone for OUD, naltrexone, Sublocade, Brixadi, Suboxone, Subutex, Butrans, Belbuca, integrative chiropractic care, functional medicine, internal medicine oversight, El Paso Injury Medical Clinic, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas, harm reduction, COWS scoring, overdose prevention, chronic pain management, spinal decompression, manual therapy, rehabilitation, personal injury care, evidence-based addiction care, perioperative buprenorphine, pregnancy and OUD, adolescents OUD treatment, naloxone, QTc prolongation, PROMIS pain interference, patient-centered care